Effects of Bisoprolol and Atenolol on Sympathetic Nervous Activity and Central Aortic Pressure in Patients With Essential Hypertension
Launched by RUIJIN HOSPITAL · Jan 4, 2013
Trial Information
Current as of June 19, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 25\~65 years old
- • untreated essential hypertension
- • SBP 140-160mmHg \& DBP 90-100mmHg
- • Sinus rhythm
- • Resting heart rate \>70bpm
- • Can give written informed consent
- Exclusion Criteria:
- • Atrial Fibrillation (AF)/ Sick Sinus Syndrome (SSS)/ atrioventricular block 2-3 grade(AVBⅡ-Ⅲ) without pacemaker
- • Bradyarrhythmia/ hypotensive
- • Unstable Angina Pectoris (UAP)/AMI/ HF (NYHA class III - IV)
- • Uncontrolled diabetes mellitus (DM)
- • Bronchial asthma
- • Gastro-intestinal ulcer or skin ulcer
- • Liver dysfunction/ renal impairment
- • Treated with CCB (Calcium antagonists) ( except amlodipine) or other beta blocker.
- • Glaucoma
- • Known allergic/ intolerance to beta blocker
- • Pregnant or lactating women
- • Participation in another clinical study within the last 3 months
- • Legal incapacity or limited legal capacity
About Ruijin Hospital
Ruijin Hospital, affiliated with Shanghai Jiao Tong University School of Medicine, is a leading medical institution in China recognized for its commitment to advancing healthcare through innovative research and clinical trials. With a strong emphasis on patient-centered care, Ruijin Hospital integrates cutting-edge medical practices with rigorous scientific investigation. The hospital's multidisciplinary teams are dedicated to developing new therapeutic approaches, improving patient outcomes, and contributing to global medical knowledge. As a sponsor of clinical trials, Ruijin Hospital ensures adherence to the highest ethical standards and regulatory compliance, fostering an environment of collaboration and excellence in clinical research.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Shanghai, Shanghai, China
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials